

Truvada® Registration In The Developing World

Approved

1. Argentina	April 2006	23. Georgia	September 2009	45. Panama	June 2010
2. Armenia	March 2009	24. Guatemala	September 2008	46. Paraguay	November 2009
3. Aruba	July 2011	25. Guinea	June 2008	47. Philippines	January 2015
4. Benin	April 2010	26. Guyana	April 2006	48. Peru	August 2014
5. Bolivia	December 2009	27. Honduras	July 2008	49. Samoa	May 2007
6. Botswana	March 2006	28. Ivory Coast	January 2012	50. Senegal	August 2008
7. Brazil	May 2012	29. Jamaica	October 2008	51. Sint Maarten	August 2016
8. Burkina Faso	April 2008	30. Kazakhstan	October 2010	52. South Africa	April 2007
9. Cameroon	November 2010	31. Kenya	November 2010	53. Tanzania	October 2006
10. Central African Republic	March 2008	32. Kyrgyzstan	July 2009	54. Thailand	September 2008
11. Chad	February 2012	33. Madagascar	October 2017	55. Togo	September 2008
12. Chile	October 2007	34. Malawi	May 2007	56. Trinidad & Tobago	September 2008
13. Colombia	August 2010	35. Mali	March 2008	57. Uganda	January 2005
14. Congo, Dem. Rep. of the	June 2006	36. Mauritania	August 2009	58. Ukraine	May 2008
15. Congo, Rep. of the	April 2008	37. Mauritius	April 2006	59. Uruguay	March 2007
16. Costa Rica	September 2012	38. Mexico	June 2005	60. Uzbekistan	January 2010
17. Curacao	September 2009	39. Moldova	May 2008	61. Venezuela	March 2015
18. Dominican Republic	September 2016	40. Mozambique	April 2009	62. Zambia	May 2005
19. Egypt	March 2012	41. Namibia	June 2006	63. Zimbabwe	April 2009
20. El Salvador	December 2008	42. Niger	July 2007		
21. Ethiopia	November 2006	43. Nigeria	June 2006		
22. Gabon	June 2007	44. Pakistan	December 2012		

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Truvada® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.